Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

J. Remon; F. Tabbò; B. Jimenez; A. Collazo; J. de Castro; S. Novello

doi:10.1007/s12094-020-02290-1

Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

J. Remon, F. Tabbò, B. Jimenez, A. Collazo, J. de Castro, S. Novello

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

8 Citations (Scopus)

Résumé

Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

langue originale	Anglais
Pages (de - à)	1425-1429
Nombre de pages	5
journal	Clinical and Translational Oncology
Volume	22
Numéro de publication	9
Les DOIs	https://doi.org/10.1007/s12094-020-02290-1
état	Publié - 1 sept. 2020
Modification externe	Oui

Accès au document

10.1007/s12094-020-02290-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{8b67522eafc04daaaade3adc2d9da749,

title = "Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine",

abstract = "Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients{\textquoteright} outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.",

keywords = "ALK, Liquid biopsy, Next-generation, Non-small cell lung cancer, Sequential treatment",

author = "J. Remon and F. Tabb{\`o} and B. Jimenez and A. Collazo and {de Castro}, J. and S. Novello",

note = "Publisher Copyright: {\textcopyright} 2020, Federaci{\'o}n de Sociedades Espa{\~n}olas de Oncolog{\'i}a (FESEO).",

year = "2020",

month = sep,

day = "1",

doi = "10.1007/s12094-020-02290-1",

language = "English",

volume = "22",

pages = "1425--1429",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

number = "9",

}

TY - JOUR

T1 - Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

AU - Remon, J.

AU - Tabbò, F.

AU - Jimenez, B.

AU - Collazo, A.

AU - de Castro, J.

AU - Novello, S.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

AB - Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

KW - ALK

KW - Liquid biopsy

KW - Next-generation

KW - Non-small cell lung cancer

KW - Sequential treatment

UR - http://www.scopus.com/inward/record.url?scp=85078289456&partnerID=8YFLogxK

U2 - 10.1007/s12094-020-02290-1

DO - 10.1007/s12094-020-02290-1

M3 - Review article

C2 - 31955355

AN - SCOPUS:85078289456

SN - 1699-048X

VL - 22

SP - 1425

EP - 1429

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 9

ER -